SCHEMBL805155

SCHEMBL805155

CCc1ccc(-c2ccc(OC)cc2)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
KDM4E B2RXH2 3/20 0.60
MAPT P10636 3/20 0.60
PKM P14618 2/20 0.60
ALOX5 P09917 1/20 0.59
PTGS1 P23219 1/20 0.59
PTGS2 P35354 1/20 0.59
NQO2 P16083 2/20 0.50
EGFR P00533 1/20 0.49
HTR1A P08908 2/20 0.48
DRD2 P14416 2/20 0.48
HTR2A P28223 2/20 0.48
HTR7 P34969 2/20 0.48
HTR6 P50406 2/20 0.48
ABCB1 P08183 1/20 0.48
PDE4B Q07343 1/20 0.45
PDE4D Q08499 1/20 0.45
PDE4A P27815 1/20 0.43
MAOB P27338 1/20 0.42
CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10050008 0.79 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTPKMALOX5
SCHEMBL19568041 0.79 ALOX5 (0.51) ALDH1A1KDM4EMAPTPKMALOX5
SCHEMBL28129468 0.77 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTPKMNQO2
SCHEMBL13680867 0.77 ALDH1A1 (0.63) ALDH1A1KDM4EMAPTPKMALOX5
SCHEMBL9970929 0.77 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTPKMALOX5
SCHEMBL2056342 0.77 ALDH1A1 (0.62) ALDH1A1KDM4EMAPTPKMALOX5
SCHEMBL805141 0.76 CYP2C19 (0.64) ALDH1A1KDM4EMAPTPKMALOX5
SCHEMBL18177326 0.76 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTPKMNQO2
SCHEMBL4316913 0.75 LTA4H (0.56) ALDH1A1KDM4EMAPTPKMPDE4B
SCHEMBL31730912 0.75 ALOX5 (1.00) ALDH1A1KDM4EMAPTALOX5PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CORNERSTONE THERAPEUTICS, INC. (US) 2012-03-22 US disclosed
US-7943622-B2 Piperazines, pharmaceutical compositions and methods of use thereof CORNERSTONE THERAPEUTICS, INC. (US) 2011-05-17 US disclosed
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CHRNA7, CHRNA5, CHRNA2 ALDH1A1 1032/4885KDM4E 3410/4885MAPT 2141/4885
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof CHRNA7, CHRNA5, CHRNA2 ALDH1A1 1032/4885KDM4E 3410/4885MAPT 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.